Sophiris Bio Corp

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

1 in Phase 3

Quick facts

Phase 3 pipeline

PRX302 · Oncology
PRX302 is a serine protease that selectively activates protease-activated receptor 1 (PAR1) in the prostate to induce localized tissue destruction and immune activation.

Phase 1 pipeline

PSA-Activated PSA-PAH1

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

Sophiris Bio Corp portfolio CI brief
Sophiris Bio Corp pipeline updates RSS

Frequently asked questions about Sophiris Bio Corp

What is Sophiris Bio Corp's pipeline?

Sophiris Bio Corp has 1 drugs in Phase 3, 0 in Phase 2, 1 in Phase 1. Late-stage candidates include PRX302.

Sector hub: All tracked pharma companies